A Randomized, Observer-Blinded, Placebo-Controlled Phase I Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of One Dose Booster by A Lyophilized COVID-19 mRNA Vaccine in Adults Aged 18 to 60 Years

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 03 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lyophilized mRNA lipid nanoparticle vaccine Wuhan Recogen Biotechnology (Primary)
Indications COVID 2019 infections
Focus Adverse reactions
Sponsors Wuhan Rhecogen Biotechnology

Most Recent Events

25 Apr 2023 Status changed from planning to withdrawn prior to enrolment.
29 Jun 2022 New trial record
27 Jun 2022 According to a Jiangsu Recbio Technology media release, company has recently received the clinical trial approval for its R520A, from the Food and Drug Administration of the Philippines.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight